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ABSTRACT 
 
Stem cell based therapy was very attractive in decompensated liver cirrhosis currently. 
The possible mechanism might be due to its potential to help tissue regeneration with mini-
mally invasive procedures. Here we report the case of a 44-year-old man, infected by hepatitis 
B virus (HBV) combined with hepatitis C virus (HCV) for longer than 10 years, who eventu-
ally developed decompensated liver cirrhosis. After being infused with mobilized peripheral 
blood stem cells, the patient showed significantly elevated serum albumin level, cholesterol 
(CHO), cholinesterase (CHE) and decreased PT (prothrombin time) during the 26 months of 
follow-up. To our knowledge, this is the first case of transplanting mobilized PBSCs to treat 
the HBV combined with HCV related decompensated liver cirrhosis.  
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INTRODUCTION 
 
 
Decompensated liver cirrhosis was one 
of the most common end-stage liver dis-
eases in China (Liu and Fan, 2007). Cur-
rently, liver transplant provides the only 
definite cure, but it is limited by donor or-
gans, operative damage, risk of rejection, 
and high costs. Therefore, an alternative 
therapy to improve liver function of the 
cirrhotic patients was more urgent.  
There were several reports that 
bone-marrow (BM) derived stem cells 
might accelerate the recovery and im-
provement of the liver function in the ani-
mal model of liver injury (Wang et al., 2003; 
Korbling et al., 2002; Lagasse et al., 2000). 
Based on the results of animal experiments, 
a few clinical trials showed that bone mar-
row-derived stem cells or granulocyte-
colony stimulating factor (G-CSF)-
mobilized bone marrow-derived hemato-
poietic stem cells could contribute to the 
liver function of the cirrhotic (Terai et al., 
2006; Yannaki et al.,2006; am Esch et 
al.,2005; Gordon et al., 2006; Lorenzini and 
Andreone, 2007). In our previous study, we 
have demonstrated that peripheral blood 
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monocytes from patients with HBV related 
decompensated liver cirrhosis could differ-
entiate into functional hepatocytes and con-
tribute to liver function (Yan et al., 2007), 
although this matter was still discussed 
controversially by the previous reports 
(Nussler et al., 2006; Hengstler et al., 2005). 
Although all the preliminary results seemed 
to be attractive, the follow-up time of the 
treated patients was too short to fully 
evaluate the safety and efficacy of stem cell 
therapy in liver cirrhosis. Here, we describe 
the case of one patient with decompensated 
liver cirrhosis causing by HBV combined 
with HCV, as a result of lasting ameliora-
tion of the clinical course with infusion of 
mobilized peripheral blood stem cells. 
 
CASE REPORT 
 
A 44-year-old man was admitted to Xijing 
Hospital in August 2005 for a detailed ex-
amination of liver dysfunction. Laboratory 
data disclosed the following abnormal val-
ues: Total Protein (TP) 53 g/L (normal 
60–87), Albumin (ALB) 31 g/L (37–55), To-
tal Bilirubin (TBIL) 19.4 µmol/L (6–19.2), 
Cholesterol (CHO) 2.23 mmol/L (3.50-6.50), 
Prothrombin Time (PT) 19.2 S (10.5-12.8), 
Activated Partial Thromboplastin Time 
(APTT) 49.9 S (26.8-37.5), Fibrinogen (FIB) 
1.92 g/L (2.0-4.0), Thrombin Time (TT) 
21.2 S (14.2-19.6), Prothrombin Activity (AT ) 
58.9 % (83-96%), International Normalized 
Ratio (INR) 1.60 (0.92-1.11), cholinesterase 
(CHE) 3021 IU/L (5300–12900). Peripheral 
blood studies disclosed white blood cell count 
at 1.53×109/L (3.5-10×109/L) (neutrophils 
49.6 %, lymphocytes 33.3 %, monocytes 
9.2 %, eosinophils 7.2 %, basophils 0.7 %), 
HGB 93 g/L (115-180) and platelets 
27×109/L (80-300×109/L). Virus markers 
were positive for Hepatitis B surface anti-
gen(HBsAg), Hepatitis B core antibody 
(HBcAb), and Hepatitis C virus antibody 
(HCVAb), negative for Hepatitis B surface 
antibody (HBs-Ab), Hepatitis B e antigen 
(HBe Ag), Hepatitis B e antibody (HBe-Ab) 
and human immunodeficiency virus (HIV); 
HBV DNA was 9.5×106 copy/ml (< 1000). 
A questionnaire revealed that the patient 
was infected by HBV combined with HCV 
11 years before, and had undergone an ex-
amination for liver function and was diag-
nosed with chronic hepatitis B combined 
with hepatitis C. He had no history of al-
cohol abuse or blood transfusion. His 
spouse was negative for HBsAg and 
HCVAb. A physical examination showed 
that he had mild abdominal distention, 
splenomegaly, gingival bleeding, jaundice, 
and edema of lower limbs. No lymphade-
nopathy or skin rash was observed. Ultra-
sound disclosed a cirrhotic liver, splenome-
galy, and mild ascites. Gastroendoscopy 
revealed an esophageal varix, and a gastric 
scattered congestion. Histological findings 
of liver biopsy were not done for the pa-
tient’s refusal. 
Liver transplant was rejected by the pa-
tients and their family members. Autolo-
gous PBSCT was carried out in this patient 
after he assigned a formal written informed 
consent. The patient was mobilized with 
recombinant human granulocyte colony 
stimulating factor (rhG-CSF, Qi Lu Phar-
maceutical Co, LTD, China) at 
5-10 µg/kg/d administered subcutaneously 
daily for 4 days to induce the bone mar-
row-derived stem cells into the peripheral 
blood, then PBSC was collected by means 
of Apheresis, using the COBE(R) Spectra 
TM Apheresis System (Gambro BCT Inc, 
Stockholm, Sweden). The duration of the 
procedure was 3 hours until the number of 
PBSC reached 108/ml. Then, 50 ml of the 
PBSC was returned to the patients via he-
patic artery in the Imaging Department. Pa-
tients were discharged after 5 days’ bed rest. 
The therapy project above was approved by 
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the ethics committee of Xijing hospital of 
the Fourth Military Medical University. The 
patient was followed-up to 26 months to 
evaluate the clinical effect of PBSCT. Dur-
ing the follow-up period, medication was 
unchanged and the patient did not receive 
antiviral therapies. Liver function related 
serum markers including albumin, alanine 
aminotransferase (ALT), aspartate ami-
notransferase (AST), TBIL, CHO, CHE, 
and prothrombin time were assayed to 
evaluate the liver function. Liver of the pa-
tient was also examined by abdominal ul-
trasonography. The results of the follow-up 
study indicated that liver synthetic function 
related markers including serum albumin, 
CHO, and CHE were significantly in-
creased after PBSCT (Figure 1), and 
prothrombin time was decreased after 
PBSCT (Figure 2).  
 
 
Figure 1: After PBSCT, serum ALB, CHO 
and CHE were significantly increased dur-
ing the follow-up. 
 
 
Figure 2: After PBSCT, prothrombin time 
was decreased during the follow-up. 
 
However, data for ALT, AST, and TBIL 
did not show significant changes after 
PBSCT, and serum HBV-DNA copy also 
didn’t show significant changes at all (data 
not shown). Abdominal ultrasonography 
showed that ascites was disappeared at 2 
weeks after PBSCT. Taken together, the 
cirrhotic patient showed a lasting ameliora-
tion of clinical course after PBSCT. 
 
DISCUSSION 
 
Bone marrow-derived stem cells were 
known to contribute to the cirrhotic livers 
currently (Mohamadnejad et al., 2007; Ab-
del Aziz et al., 2007). HBV-related or  
HCV-related decompensated liver cir-
rhosis was very common worldwide, espe-
cially in China, because there were about 
more than 10 % HBV carriers. Once the 
decompensated liver cirrhosis occurred, 
liver transplant provides the only definite 
cure; however, postoperative recurred virus 
related hepatitis or tumor limited is widely 
used. Stem cell based therapy provides one 
inspiring therapy for hepatitis virus related 
decompensated liver cirrhosis.  
This is the first report about evaluating 
liver function of HBV combined with HCV 
related cirrhotic patient who underwent 
PBSCT. In addition, the time of follow-up 
was the longest compared with other re-
ports about PBSCT contributing to liver 
function of decompensated liver cirrhosis. 
After PBSCT, the patient acquired lasting 
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amelioration of the liver function, which 
included liver synthetic function related 
markers including serum albumin; CHO, 
CHE, and prothrombin time were signifi-
cantly improved after PBSCT. However, 
serum ALT, AST, and TBIL did not show 
significant changes after PBSCT, indicating 
that G-CSF mobilization combined with 
PBSCT therapy could not change the con-
dition of virus copy. What’s more, serum 
HBV-DNA copy was still unchanged during 
the follow-up. There were two factors in-
volved in the lasting amelioration of the 
clinical course, including G-CSF mobiliza-
tion and PBSCT. G-CSF is a pleiotropic 
cytokine that plays a major role in regulat-
ing hematopoiesis and innate immune re-
sponses (Franzke, 2006). A recent study 
reported that G-CSF could mobilize BM 
stem cells into infarcted cardiac tissue and 
accelerates their differentiation into vascu-
lar cells and cardiac myocytes (Takano et 
al., 2006), and the effect of G-CSF has also 
been demonstrated in Crohn’s disease and 
ulcerative colitis (Baert and Rutgeerts, 
2000). Moreover, a current report demon-
strated that hematopoietic mobilization 
could increase the presence of bone mar-
row–derived hepatocytes via in vivo cell 
fusion (Quintana-Bustamante et al., 2006). 
Thus, our favorable result might be ex-
plained both by G-CSF mobilization and 
PBSCT. Firstly, G-CSF could mobilize a 
large number of PBSCs into the circulation 
and secret some cytokines or growth factors 
to promote hepatocytes functions by 
paracrine mechanisms. Secondly, trans-
planted PBSC via hepatic artery might in-
duce the higher concentration of PBSC 
homing to the injured liver and contribute 
to the liver function by cell differentiation 
or fusion. To fully demonstrate the thera-
peutic value of this protocol, results of 
long-term follow-up in more patients with 
hepatitis related cirrhosis are needed. 
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